Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer–Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: There are no specific treatment guidelines for diabetes of the exocrine pancreas. High-quality studies are warranted to investigate whether the use of antidiabetic medications has survival benefit in individuals with diabetes of the exocrine pancreas. The objective was to determine the risk of mortality associated with the use of antidiabetic medications in individuals with pancreatic cancer–related diabetes (PCRD) and postpancreatitis diabetes mellitus (PPDM). RESEARCH DESIGN AND METHODS: Nationwide pharmaceutical dispensing data (2006–2015) linked to hospital discharge data were used to identify 1,862 individuals with PCRD or PPDM. Multivariable Cox regression analysis was conducted, and the risk was expressed as hazard ratios and 95% CIs. A 6-month lag was used to minimize reverse causality. RESULTS: In individuals with PCRD, ever users of metformin (adjusted hazard ratio 0.54; 95% CI 0.46–0.63) and ever users of insulin (adjusted hazard ratio 0.46; 95% CI 0.39–0.55) had significantly lower risks of mortality compared with never users of antidiabetic medications. These associations attenuated toward the null with the use of a 6-month lag. In individuals with PPDM, ever users of metformin had a significantly lower risk of mortality (adjusted hazard ratio 0.51; 95% CI 0.36–0.70), whereas ever-users of insulin did not have a significantly changed risk of mortality (adjusted hazard ratio 0.75; 95% CI 0.49–1.14) compared with never users of antidiabetic medications. The former association remained significant with the use of a 6-month lag. CONCLUSIONS: Metformin promotes a survival benefit in individuals with PPDM but not PCRD. Reverse causality may play a role in the association between insulin use and mortality in PCRD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Gregg, E. W., Cheng, Y. J., Srinivasan, M., Lin, J., Geiss, L. S., Albright, A. L., & Imperatore, G. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30314-3 · Cited by 480 · cited 1×
“1 times higher risk of mortality than those without diabetes (1,2).”
BackgroundWoodmansey, C., McGovern, A. P., McCullough, K. A., Whyte, M. B., Munro, N. M., Correa, A. C., Gatenby, P. A. C., Jones, S. A., & de Lusignan, S. (2017) · Diabetes Care · doi:10.2337/dc17-0542 · Cited by 280 · cited 4×
“showed that insulin is used frequently in this population (6).”
BackgroundInfluentialSharma, A., Smyrk, T. C., Levy, M. J., Topazian, M. A., & Chari, S. T. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.025 · Cited by 204
McGovern, A., Tippu, Z., Hinton, W., Munro, N., Whyte, M., & de Lusignan, S. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13160 · Cited by 166 · cited 1×
“Some individuals might not have used antidiabetic medications as prescribed (50).”
Background
Cited by
Shi, Y.-Q., Zhou, X.-C., Du, P., Yin, M.-Y., Xu, L., Chen, W.-J., & Xu, C.-F. (2020) · Medicine · doi:10.1097/md.0000000000021687 · Cited by 43
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
Cho, J., Scragg, R., Pandol, S. J., & Petrov, M. S. (2021) · Clinical and Translational Science · doi:10.1111/cts.12837 · Cited by 35
Self-citation
Metadata
- Authors
- Cho, J., Scragg, R., Pandol, S. J., Goodarzi, M. O., & Petrov, M. S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-06-21
- Volume
- 42
- Issue
- 9
- Pages
- 1675-1683
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2949192712
- Cited by
- 69
- References
- 7
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.